Regeneron Pharmaceuticals Inc (REGN)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- Weekly momentum+5.2% over the past week+6
- 12-month trend+40% over the past year+3
- 52-week positionPressing 52-week highs+30
- QualityRevenue growing 19% y/y+7
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is product (positive clinical data for Regeneron's heart-rate drug), with the dividend and valuation headlines acting as secondary context rather than a fundamental driver. Continuation likelihood over the next few weeks is moderate (~40–50%), since single-study readouts often fade without confirmatory data or regulatory milestones. Informational only — not financial advice.
- 4 Dividend Stocks Retirees Can Buy Before They Go Ex-Dividend in the Week AheadYahoo · 2026-11-15
- Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?Yahoo · 2026-11-14
- Could You Have Held Glaukos Stock Through Its Falls?Yahoo · 2026-11-14
- Kodiak Q3 Loss Wider Than Expected, Pipeline Development in FocusYahoo · 2026-11-13
- Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease StudyBenzinga · 2026-11-13
Any AI summary is an interpretation of public news, not advice or a price target.